Novel protein imaging method could lead to the development of new biomaterials

NewsGuard 100/100 Score

Scientists have established a new method to image proteins that could lead to new discoveries in disease through biological tissue and cell analysis and the development of new biomaterials that can be used for the next generation of drug delivery systems and medical devices.

Scientists from the University of Nottingham in collaboration with the University of Birmingham and The National Physical laboratory have used the state-of-the-art 3D OrbiSIMS instrument to facilitate the first matrix- and label-free in situ assignment of intact proteins at surfaces with minimal sample preparation. Their research has been published today in Nature Communications.

The University of Nottingham is the first University in the world to own a 3D OrbiSIMS instrument. It is able to facilitate an unprecedented level of mass spectral molecular analysis for a range of materials (hard and soft matter, biological cells and tissues). The facility in Nottingham also has high pressure freezing cryo-preparation facilities that enable biological samples to be maintained close to their native state as frozen-hydrated to complement the more commonly applied but more disruptive freeze-drying and sample fixation. When the surface sensitivity, high mass/spatial resolution are combined with a depth profiling sputtering beam, the instrument becomes an extremely powerful tool for 3D chemical analysis as demonstrated in this recent work.

Dr David Scurr from the University of Nottingham's School of Pharmacy led this latest study and was supported by PhD student Anna Kotowska. David said: "The design and innovation of the next generation of biomaterials is underpinned by the ability to accurately characterize biological tissue and materials. The challenge for scientists in this area has been unpicking the chemical complexity of such systems. This approach to protein analysis has been demonstrated using extreme examples to illustrate its sensitivity and specificity by chemically mapping a protein monolayer (protein biochip) and distribution of specific protein in human skin (complex multi-layered biological system) respectively. With the ability to chemically map proteins in this way we are a step closer to being able to understand fundamental biological processes and develop more effective systems for targeting drugs and providing coatings for medical devices."

The team in Nottingham have already applied biomaterials research to create a new type of urinary catheter in partnership with Camstent Ltd that is coated in a bacteria resistant material discovered by scientists from the University of Nottingham.

Professor Morgan Alexander is director of the EPSRC Programme Grant in Next Generation Biomaterials Discovery and the 3D OrbiSIMS facility, he said: "The research we are now able to do using this instrument is paving the way for step changes in how materials can be used in medicine to better treat disease and illness. The Catheter coating we have developed in partnership with Camstent has gone all the way from the discovery of a new class of materials that no one could have predicted all the way to clinical trials and is a great example of the application of this type of research."

With these new capabilities to characterize proteins at surfaces comes also new exciting opportunities to engineer functional materials with predictable protein interactions for biosensor technology".

Paula Mendes, Professor of Advanced Materials and Nanotechnology at the University of Birmingham

Source:
Journal reference:

Kotowska, A.M., et al. (2020) Protein identification by 3D OrbiSIMS to facilitate in situ imaging and depth profiling. Nature Communications. doi.org/10.1038/s41467-020-19445-x.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Immune cell protein identified as potential target for rare liver cancer treatment